The firm expects to replace its current screening assay with the methylation test following regulatory clearance from the country's Ministry of Food and Drug Safety.
Cancer diagnostic firms showcased their discoveries as they flesh out their DNA methylation- and fragmentation-based platforms using circulating tumor DNA.
The firm shared validation data at ASCO on its LiquidHallmark assay to help guide detection and treatment decisions for late-stage cancers.
The firm also shared validation data at ASCO 2021 on its nasal swab classifier to help guide treatment decisions for patients with indeterminate lung nodules.
The firm's panel test, which will initially cost $400, identifies genetic biomarkers linked to over 20 cancers in dogs using cell-free and genomic DNA from blood.
However, some industry experts have expressed concerns about the Santa Monica, California-based firm's lack of data and current business model.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
NeoGenomics believes Inivata's assays will contribute meaningful revenues as early as 2023, driven by both firms' existing relationships with oncology and pathology groups.
The team will use the reverse-transcriptase quantitative PCR test, which uses a milliliter of a patient's blood, to curb unneeded radical colon cancer surgeries.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.